Williams R B
Veterinary Research Division, May & Baker Ltd., Ongar, Essex, UK.
Vet Parasitol. 2006 Jan 15;135(1):1-14. doi: 10.1016/j.vetpar.2005.10.012. Epub 2005 Nov 11.
Decoquinate is a quinolone coccidiostat introduced during 1967 as an in-feed prophylactic for broiler chickens. Despite early drug-resistance problems and its age, the drug is still used commercially worldwide. Decoquinate here serves as a valuable model in a field study that addresses the dynamics and economic impact of the development of coccidial resistance to potent synthetic anticoccidial drugs. The results of this unique, hitherto unpublished, study on the initial emergence of resistance of avian coccidia (Eimeria spp.) to a new drug in the field may be of strategic value in the continued use of decoquinate or the introduction of new drugs. The commercial performance of the first 3-5 crops of broilers to be medicated with decoquinate on each of six farms was monitored during 14 months in 1968-1969, supplemented by assessments of the species, population dynamics and decoquinate-resistance of coccidia isolated from each farm. During the rearing of each flock in a single shed on each farm, oocysts were counted in fresh faecal samples collected on three occasions, and the species were identified by their morphology if possible, supported if necessary by the biological characteristics of infections in chickens. E. acervulina was the most common species, followed by E. mitis, E. maxima, E. tenella and E. praecox. E. brunetti occurred rarely, and E. necatrix was not found. Decoquinate-resistance was evident in several species during the rearing of the first decoquinate-medicated crop on each farm, although clinical coccidiosis did not occur. It was concluded that inherently resistant mutants of E. acervulina, E. brunetti, E. maxima, E. tenella, and probably also E. mitis and E. praecox, were selected from field populations by 6 weeks during their first exposure to decoquinate. During up to four more subsequent crops, cycling of resistant parasites stimulated host immunity, which had no obvious adverse impact on commercial performance. There was no apparent seasonal effect. A hypothesis is proposed to explain the sudden and rapid emergence of quinolone-resistance in the coccidia, and why bird health was not thereby compromised in these circumstances.
地考喹酯是一种喹诺酮类抗球虫药,于1967年作为肉鸡的饲料预防性药物推出。尽管早期存在耐药性问题且该药使用时间已久,但它仍在全球范围内商业使用。在地考喹酯在球虫对强效合成抗球虫药产生耐药性的动态变化及其经济影响的实地研究中,它是一个有价值的模型。这项关于禽类球虫(艾美耳属)在实地对新药产生耐药性的最初出现的独特研究(此前未发表)结果,对于地考喹酯的持续使用或新药的引入可能具有战略价值。1968 - 1969年的14个月期间,监测了六个农场中每个农场首批用 地考喹酯治疗的3 - 5批肉鸡的商业性能,并对从每个农场分离出的球虫的种类、种群动态和对地考喹酯的耐药性进行了评估。在每个农场单个鸡舍饲养每批鸡的过程中,对三次采集的新鲜粪便样本中的卵囊进行计数,并尽可能通过形态学鉴定球虫种类,必要时借助鸡感染的生物学特性进行辅助鉴定。堆型艾美耳球虫是最常见的种类,其次是微小艾美耳球虫、巨型艾美耳球虫、柔嫩艾美耳球虫和早熟艾美耳球虫。布氏艾美耳球虫很少出现,未发现毒害艾美耳球虫。在每个农场首批用地考喹酯治疗的鸡群饲养过程中,几种球虫都出现了对地考喹酯的耐药性,尽管未发生临床球虫病。得出的结论是,堆型艾美耳球虫、布氏艾美耳球虫、巨型艾美耳球虫、柔嫩艾美耳球虫以及可能还有微小艾美耳球虫和早熟艾美耳球虫的固有耐药突变体,在首次接触地考喹酯的6周内从田间种群中被筛选出来。在随后多达四批鸡的饲养过程中,耐药寄生虫的循环刺激了宿主免疫力,这对商业性能没有明显的不利影响。没有明显的季节效应。提出了一个假设来解释球虫中喹诺酮耐药性的突然快速出现,以及在这些情况下禽类健康为何未因此受到损害。